Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's DiseaseCompleted
NCT05452304Phase 1Updated Dec 3, 2025
Sponsor: AstraZeneca
Healthy Subjects · Crohns Disease
United Kingdom
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian CancerCompleted
NCT03249142Phase 1, Phase 2Updated Dec 3, 2025
Sponsor: ARCAGY/ GINECO GROUP
Ovarian Cancer
France
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)Recruiting
NCT04151342N/AUpdated Dec 3, 2025
Sponsor: University Health Network, Toronto
Cancer · Malignancies Multiple · Malignant Solid Tumor · Cancer, Therapy-Related
Canada
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World SettingsActive Not Recruiting
NCT05590702N/AUpdated Dec 3, 2025
Sponsor: French Innovative Leukemia Organisation
CLL/SLL
France
An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of TozorakimabCompleted
NCT06908577Phase 1Updated Dec 2, 2025
Sponsor: AstraZeneca
Healthy Participants
United States, Germany, United Kingdom
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR MutationsActive Not Recruiting
NCT05103605N/AUpdated Dec 1, 2025
Sponsor: AstraZeneca
Non Small Cell Lung Cancer
France
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy ParticipantsCompleted
NCT06115967Phase 1Updated Dec 1, 2025
Sponsor: AstraZeneca
Rheumatoid Arthritis
Canada, United Kingdom
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic CholangiocarcinomaRecruiting
NCT06440993Phase 2Updated Dec 1, 2025
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Extrahepatic Cholangiocarcinoma · Unresectable Perihilar or Ductal CCA
Germany
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsCompleted
NCT04008706Phase 3Updated Dec 1, 2025
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
United States, Australia, Brazil, Canada, Denmark +12 more
Retention Rate of Acalabrutinib in a Non-interventional SettingActive Not Recruiting
NCT05645172N/AUpdated Dec 1, 2025
Sponsor: AstraZeneca
Chronic Lymphocytic Leukaemia (CLL)
Germany
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Active Not Recruiting
NCT03983954Phase 1Updated Nov 28, 2025
Sponsor: NeoTX Therapeutics Ltd.
ER+ Breast Cancer · Ovarian Cancer · Cervical Squamous Cell Carcinoma · Pancreatic Adenocarcinoma
India, Israel
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-studyActive Not Recruiting
NCT06073574N/AUpdated Nov 28, 2025
Sponsor: Ionis Pharmaceuticals, Inc.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
United States, Italy, Spain, United Kingdom
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge StudyCompleted
NCT05347693Phase 4Updated Nov 28, 2025
Sponsor: AstraZeneca
Hyperkalaemia · Chronic Kidney Disease
Belgium, France, Italy, Netherlands, Spain +1 more
Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.Completed
NCT06321731N/AUpdated Nov 28, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Spain
The CARDIO-TTRansform Scintigraphy Sub-studyActive Not Recruiting
NCT06073587N/AUpdated Nov 28, 2025
Sponsor: Ionis Pharmaceuticals, Inc.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
United States, Spain
Basket Study for Oligo-metastatic Breast CancerRecruiting
NCT05982678Phase 2Updated Nov 26, 2025
Sponsor: The Netherlands Cancer Institute
HER2-positive Breast Cancer
Netherlands
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLCRecruiting
NCT07058519Phase 2Updated Nov 26, 2025
Sponsor: Shanghai Chest Hospital
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
China
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast CancerActive Not Recruiting
NCT01992952Phase 1, Phase 2Updated Nov 26, 2025
Sponsor: Velindre NHS Trust
Estrogen Receptor Positive Breast Cancer
United Kingdom
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.Completed
NCT06675175Phase 1Updated Nov 25, 2025
Sponsor: AstraZeneca
Chronic Kidney Disease · Atherosclerotic Cardiovascular Disease
United States, Bulgaria, Hungary, Romania
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)Completed
NCT03109080Phase 1Updated Nov 24, 2025
Sponsor: Institut Curie
Breast Neoplasms, Triple-Negative · Breast Neoplasm Malignant Female · Radiotherapy Side Effect
France
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)Withdrawn
NCT06575517N/AUpdated Nov 24, 2025
Sponsor: AstraZeneca
Bleeding
HF Prevalence and Evolution of HF in DM II Patients at High RiskCompleted
NCT04482283N/AUpdated Nov 24, 2025
Sponsor: AstraZeneca
RELATED REGISTRY SEARCH
Greece
Real-world Dapagliflozin Experience in Patients With Heart Failure in GreeceCompleted
NCT05635331N/AUpdated Nov 24, 2025
Sponsor: AstraZeneca
Heart Failure
Greece
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian PatientsRecruiting
NCT06429761Phase 4Updated Nov 24, 2025
Sponsor: AstraZeneca
BREAST CANCER
India
Imjudo & Imfinzi PMSRecruiting
NCT06544629N/AUpdated Nov 21, 2025
Sponsor: AstraZeneca
Hepatocellular Carcinoma
South Korea

Previous page Next page